Literature DB >> 15485601

Combination drug treatment of hypertension: have we come full circle?

Addison A Taylor1.   

Abstract

Only 30% of hypertensive patients achieved and maintained adequate blood pressure control on a single drug in recent clinical trials. For the majority of patients who require two or more drugs to lower blood pressure to the currently recommended goals of 140/90 mm Hg or to 130/80 if they are diabetic or have chronic kidney disease, combinations of two or more drugs in a single pill offers an attractive alternative to taking multiple single drugs each day. Research has shown that the simpler the drug regimen the more likely patients are to be compliant in taking medications. Because a reduction in cardiovascular risk is linked to the extent to which elevated blood pressure is reduced, this benefit is not realized by patients who either discontinue their medications or are noncompliant. Carefully selected low doses of two antihypertensive drugs combined in a single pill offers other advantages including greater efficacy compared with high-dose monotherapy, a lower incidence of adverse effects, improved persistence in taking medications, fewer patient visits, and reduced cost to the health care system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485601     DOI: 10.1007/s11886-004-0049-0

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  42 in total

1.  A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension.

Authors:  C M Dezii
Journal:  Manag Care       Date:  2001-02

Review 2.  Pharmacological basis for combination therapy of hypertension.

Authors:  C T Dolley
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

3.  Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.

Authors:  F H Messerli; S Oparil; Z Feng
Journal:  Am J Cardiol       Date:  2000-12-01       Impact factor: 2.778

4.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

5.  Reserpine-hydralazine combination therapy of hypertensive disease, with hydralazine in doses generally below the toxic range.

Authors:  R E LEE; A M SELIGMANN; D GOEBEL; L A FULTON; M A CLARK
Journal:  Ann Intern Med       Date:  1956-03       Impact factor: 25.391

6.  Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects.

Authors:  A J Jounela; M Lilja; J Lumme; C Mörlin; A Hoyem; T Wessel-Aas; N J Borrild
Journal:  Blood Press       Date:  1994-07       Impact factor: 2.835

7.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

8.  Patients' experiences of antihypertensive drugs in routine use: results of a Danish general practice survey.

Authors:  N J Borrild
Journal:  Blood Press Suppl       Date:  1997

9.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

Authors:  Jan A Staessen; Ji-Guang Wang; Lutgarde Thijs
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

10.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

View more
  9 in total

Review 1.  Should two-drug initial therapy for hypertension be recommended for all patients?

Authors:  Jennifer B Cowart; Addison A Taylor
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

2.  Use of combination antihypertensive therapy initiation in older Americans without prevalent cardiovascular disease.

Authors:  Xiaojuan Li; Wendy Camelo Castillo; Til Stürmer; Virginia Pate; Christine L Gray; Ross J Simpson; Soko Setoguchi; Laura C Hanson; Michele Jonsson Funk
Journal:  J Am Geriatr Soc       Date:  2014-08-12       Impact factor: 5.562

Review 3.  Combination pharmacotherapy in hypertension.

Authors:  George S Stergiou
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

4.  Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility.

Authors:  David T Nash; Michael S McNamara
Journal:  Integr Blood Press Control       Date:  2009-10-28

5.  Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study.

Authors:  Samir H Assaad-Khalil; Nashwa Nashaat
Journal:  Drugs Real World Outcomes       Date:  2016-09

Review 6.  Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.

Authors:  Christina Antza; Stella Stabouli; Vasilios Kotsis
Journal:  Vasc Health Risk Manag       Date:  2016-11-15

Review 7.  Current status of stroke in Qatar: Including data from the BRAINS study.

Authors:  Ebrima Jallow; Hassan Al Hail; Thang S Han; Sapna Sharma; Dirk Deleu; Musab Ali; Hassan Al Hussein; Hassan O Abuzaid; Khalid Sharif; Fahmi Y Khan; Pankaj Sharma
Journal:  JRSM Cardiovasc Dis       Date:  2019-08-18

Review 8.  What factors contribute to the inadequate control of elevated blood pressure?

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

Review 9.  Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Vasc Health Risk Manag       Date:  2009
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.